LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 224

Suchoptionen

  1. Artikel ; Online: Continuous and Intermittent Glucose Monitoring in 2023.

    Dovc, Klemen / Bode, Bruce W / Battelino, Tadej

    Diabetes technology & therapeutics

    2024  Band 26, Heft S1, Seite(n) S14–S31

    Mesh-Begriff(e) Humans ; Blood Glucose Self-Monitoring ; Blood Glucose
    Chemische Substanzen Blood Glucose
    Sprache Englisch
    Erscheinungsdatum 2024-03-05
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1452816-2
    ISSN 1557-8593 ; 1520-9156
    ISSN (online) 1557-8593
    ISSN 1520-9156
    DOI 10.1089/dia.2024.2502
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Continuous and Intermittent Glucose Monitoring in 2022.

    Dovc, Klemen / Bode, Bruce W / Battelino, Tadej

    Diabetes technology & therapeutics

    2023  Band 25, Heft S1, Seite(n) S15–S29

    Mesh-Begriff(e) Humans ; Blood Glucose ; Blood Glucose Self-Monitoring
    Chemische Substanzen Blood Glucose
    Sprache Englisch
    Erscheinungsdatum 2023-02-09
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1452816-2
    ISSN 1557-8593 ; 1520-9156
    ISSN (online) 1557-8593
    ISSN 1520-9156
    DOI 10.1089/dia.2023.2502
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Buch: Enhancing patient success with GLP-1 analogs

    Kruger, Davida F. / Bode, Bruce W. / Spollett, Geralyn R.

    presented live at the American Association of Diabetes Educators' (AADE'S) 2009 annual meeting in Atlanta, Georgia, on August 7, 2009

    (The diabetes educator ; 36, Suppl. 3 ; Cases in practice)

    2010  

    Titelvarianten Cases in practice
    Körperschaft American Association of Diabetes Educators
    Verfasserangabe [Davida F. Kruger, Bruce Bode and Geralyn R. Spollett]
    Serientitel The diabetes educator ; 36, Suppl. 3
    Cases in practice
    Diabetes educator
    Überordnung Diabetes educator
    Sprache Englisch
    Umfang S. 44S - 74S : Ill., graph. Darst.
    Verlag Sage
    Erscheinungsort Thousand Oaks, CA
    Erscheinungsland Vereinigte Staaten
    Dokumenttyp Buch
    HBZ-ID HT016504998
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

  4. Artikel ; Online: Continuous and Intermittent Glucose Monitoring in 2021.

    Dovc, Klemen / Bode, Bruce W / Battelino, Tadej

    Diabetes technology & therapeutics

    2022  Band 24, Heft S1, Seite(n) S209–S219

    Mesh-Begriff(e) Blood Glucose ; Blood Glucose Self-Monitoring ; Glycated Hemoglobin A/analysis ; Humans ; Hypoglycemia
    Chemische Substanzen Blood Glucose ; Glycated Hemoglobin A
    Sprache Englisch
    Erscheinungsdatum 2022-05-03
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1452816-2
    ISSN 1557-8593 ; 1520-9156
    ISSN (online) 1557-8593
    ISSN 1520-9156
    DOI 10.1089/dia.2022.2514
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod

    DeSalvo, Daniel J / Bode, Bruce W / Forlenza, Gregory P / Laffel, Lori M / Buckingham, Bruce A / Criego, Amy B / Schoelwer, Melissa / MacLeish, Sarah A / Sherr, Jennifer L / Hansen, David W / Ly, Trang T

    Diabetes technology & therapeutics

    2024  

    Abstract: Background: ...

    Abstract Background:
    Sprache Englisch
    Erscheinungsdatum 2024-02-21
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1452816-2
    ISSN 1557-8593 ; 1520-9156
    ISSN (online) 1557-8593
    ISSN 1520-9156
    DOI 10.1089/dia.2023.0506
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel: Can Faster Aspart Be Used to Optimize Glycemic Control With Insulin Pump Therapy? From Expectations to Lessons Learned After a Year of Use in the United States.

    Aleppo, Grazia / Bode, Bruce / Carlson, Anders L

    Clinical diabetes : a publication of the American Diabetes Association

    2022  Band 40, Heft 4, Seite(n) 413–424

    Abstract: Fast-acting insulin aspart (faster aspart) is an ultra-rapid-acting formulation of insulin aspart developed to more closely match the prandial endogenous insulin profile, and its accelerated absorption kinetics are expected to provide clinical benefits ... ...

    Abstract Fast-acting insulin aspart (faster aspart) is an ultra-rapid-acting formulation of insulin aspart developed to more closely match the prandial endogenous insulin profile, and its accelerated absorption kinetics are expected to provide clinical benefits for patients using insulin pump therapy. A head-to-head trial versus the original insulin aspart formulation in pump therapy did not demonstrate superiority of faster aspart in terms of A1C reduction, but pump settings were not optimized for the pharmacokinetic/pharmacodynamic profile of faster aspart. Nevertheless, meal test and continuous glucose monitoring data suggest that faster aspart is beneficial for postprandial glucose control, and a case study is presented illustrating excellent results using this insulin in pump therapy. Frequent blood glucose monitoring and appropriate patient education are vital for success.
    Sprache Englisch
    Erscheinungsdatum 2022-10-21
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1025953-3
    ISSN 0891-8929
    ISSN 0891-8929
    DOI 10.2337/cd21-0056
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Continuous and Intermittent Glucose Monitoring in 2020.

    Bode, Bruce W / Battelino, Tadej / Dovc, Klemen

    Diabetes technology & therapeutics

    2021  Band 23, Heft S2, Seite(n) S16–S31

    Mesh-Begriff(e) Blood Glucose ; Blood Glucose Self-Monitoring ; Glycated Hemoglobin A/analysis ; Humans ; Hypoglycemia
    Chemische Substanzen Blood Glucose ; Glycated Hemoglobin A
    Sprache Englisch
    Erscheinungsdatum 2021-06-01
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1452816-2
    ISSN 1557-8593 ; 1520-9156
    ISSN (online) 1557-8593
    ISSN 1520-9156
    DOI 10.1089/dia.2021.2502
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Continuous Glucose Monitoring in 2018.

    Bode, Bruce W / Battelino, Tadej

    Diabetes technology & therapeutics

    2019  Band 21, Heft S1, Seite(n) S13–S31

    Mesh-Begriff(e) Adult ; Blood Glucose/analysis ; Blood Glucose Self-Monitoring/history ; Blood Glucose Self-Monitoring/methods ; Diabetes Mellitus, Type 1/blood ; Diabetes Mellitus, Type 1/drug therapy ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/drug therapy ; Female ; History, 21st Century ; Humans ; Hypoglycemic Agents/therapeutic use ; Insulin/therapeutic use ; Male
    Chemische Substanzen Blood Glucose ; Hypoglycemic Agents ; Insulin
    Sprache Englisch
    Erscheinungsdatum 2019-02-12
    Erscheinungsland United States
    Dokumenttyp Historical Article ; Journal Article ; Review
    ZDB-ID 1452816-2
    ISSN 1557-8593 ; 1520-9156
    ISSN (online) 1557-8593
    ISSN 1520-9156
    DOI 10.1089/dia.2019.2502
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Konferenzbeitrag: Assessing time in range (TIR) with postprandial glucose (PPG)-focused titration of ultra rapid lispro (URLi) in patients (pts) with type 1 diabetes (T1D)

    Bergenstal, Richard / Bode, Bruce / Bhargava, Anuj / Wang, Qianqian / Chang, Anne / Wiesner, Tobias

    Diabetologie und Stoffwechsel

    2023  Band 18, Heft S 01

    Veranstaltung/Kongress Diabetes Kongress 2023 - 57. Jahrestagung der DDG, CityCube Berlin, 2023-05-17
    Sprache Deutsch
    Erscheinungsdatum 2023-04-01
    Verlag Georg Thieme Verlag
    Erscheinungsort Stuttgart ; New York
    Dokumenttyp Artikel ; Konferenzbeitrag
    ZDB-ID 2222993-0
    ISSN 1861-9010 ; 1861-9002
    ISSN (online) 1861-9010
    ISSN 1861-9002
    DOI 10.1055/s-0043-1767953
    Datenquelle Thieme Verlag

    Zusatzmaterialien

    Kategorien

  10. Artikel: Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in Range.

    Bailey, Timothy S / Bode, Bruce W / Wang, Qianqian / Knights, Alastair W / Chang, Annette M

    Diabetes therapy : research, treatment and education of diabetes and related disorders

    2023  Band 14, Heft 5, Seite(n) 883–897

    Abstract: Introduction: To evaluate time in range metrics and HbA1c in people with type 2 diabetes (T2D) treated with ultra rapid lispro (URLi) using continuous glucose monitoring (CGM) for the first time in this population.: Methods: This was a Phase 3b, 12- ... ...

    Abstract Introduction: To evaluate time in range metrics and HbA1c in people with type 2 diabetes (T2D) treated with ultra rapid lispro (URLi) using continuous glucose monitoring (CGM) for the first time in this population.
    Methods: This was a Phase 3b, 12-week, single-treatment study in adults with T2D on basal-bolus multiple daily injection (MDI) therapy using basal insulin glargine U-100 along with a rapid-acting insulin analog. Following a 4-week baseline period, 176 participants were newly treated with prandial URLi. Participants used unblinded CGM (Freestyle Libre). Primary endpoint was time in range (TIR) (70-180 mg/dl) during the daytime period at Week 12 compared to baseline with gated secondary endpoints of HbA1c change from baseline and 24-h TIR (70-180 mg/dl).
    Results: Improved glycemic control was observed at Week 12 versus baseline including mean daytime TIR (change from baseline [Δ] 3.8%; P = 0.007), HbA1c (Δ - 0.44%; P < 0.001), and 24-h TIR (Δ 3.3%; P = 0.016) with no significant difference in time below range (TBR). After 12 weeks, there was a statistically significant decrease in postprandial glucose incremental area under curve, overall, across all meals, within 1 h (P = 0.005) or 2 h (P < 0.001) after the start of a meal. Basal, bolus, and total insulin dose were intensified with increased bolus/total dose ratio at Week 12 (50.7%) versus baseline (44.5%; P < 0.001). There were no severe hypoglycemia events during the treatment period.
    Conclusions: In people with T2D, URLi in an MDI regimen was efficacious with improved glycemic control including TIR, HbA1c, and postprandial glucose without increased hypoglycemia/TBR. CLINICAL TRIAL REGISTRATION NUMBER: NCT04605991.
    Sprache Englisch
    Erscheinungsdatum 2023-04-07
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2566702-6
    ISSN 1869-6961 ; 1869-6953
    ISSN (online) 1869-6961
    ISSN 1869-6953
    DOI 10.1007/s13300-023-01400-w
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang